{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040628","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.843827+00:00","generated_at":"2026-06-11T23:27:58.594898+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tenaya Q2 net loss $33.3M; TN-201 first patient dosing on track for Q3 2023","bullets":["Cash and investments $151.6M; runway into first half 2025.","R&D expense $26.5M; G&A expense $8.6M; net loss $0.45/share.","First patient in MyPeak-1 Phase 1b trial of TN-201 expected in Q3 2023.","Data from TN-301 Phase 1 trial accepted for HFSA October 2023.","IND for TN-401 PKP2 gene therapy planned for H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040628","json":"https://secwatch.observer/filing/0000950170-23-040628.json","markdown":"https://secwatch.observer/filing/0000950170-23-040628.md","text":"https://secwatch.observer/filing/0000950170-23-040628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/0000950170-23-040628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/tnya-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:27:58.594898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95a1d83573b5686b1f74db330ffa08778a0c43db","claim":"Tenaya Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $33.3 million, EPS $0.45 per share.","evidence_excerpt":"Net loss for the quarter ended June 30, 2023, was $33.3 million, or $0.45 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/0000950170-23-040628-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$33.3 million"},{"label":"EPS","value":"$0.45 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}